目的:探究卵巢癌(ovarian cancer,OV)浸润性CD4^(+)调节性T细胞(regulatory T cell,Treg)的脂质摄取与积累情况,及其与CD4^(+)Treg中程序性细胞死亡蛋白1(programmed cell death protein 1,PD-1)和细胞毒性T淋巴细胞相关蛋白-4(cytotoxi...目的:探究卵巢癌(ovarian cancer,OV)浸润性CD4^(+)调节性T细胞(regulatory T cell,Treg)的脂质摄取与积累情况,及其与CD4^(+)Treg中程序性细胞死亡蛋白1(programmed cell death protein 1,PD-1)和细胞毒性T淋巴细胞相关蛋白-4(cytotoxic Tlymphocyte associated protein 4,CTLA-4)表达的相关性。方法:采用亲脂性荧光染料BODIPY^(TM)493/503和荧光脂肪酸探针BODIPY^(TM)500/510 C1 C12分别检测OV组织中的或与不同OV细胞系(ES-2、SKOV3、CAOV3)上清液共培养的人源CD4^(+)Treg的细胞内脂质含量和脂质摄取能力;使用脂肪酸氧化抑制剂(Etomoxir)、脂肪酸合成抑制剂(C75)和脂肪酸摄取抑制剂磺基-N-琥珀酰亚胺油酸酯(sulfo-N-succinimidyl oleate,SSO)干预脂质代谢;通过流式细胞术分析CD4^(+)Treg上免疫抑制分子PD-1和CTLA-4的表达。结果:OV组织CD4^(+)Treg相比传统CD4^(+)T细胞表现出更高的脂质含量和脂质摄取能力(P均<0.01)。在体外实验中,与基础培养基相比,OV细胞培养上清可显著提升CD4^(+)Treg的胞内脂质含量与脂质摄取能力(P均<0.05),其中CAOV3来源的上清作用最为显著。此外,CAOV3上清液还能提升CD4^(+)Treg中PD-1与CTLA-4的表达(P<0.05)。CD4^(+)Treg的脂质积累随CAOV3上清浓度增加呈剂量依赖性上升(P<0.05),且其对胞外荧光脂肪酸类似物的摄取能力具有浓度依赖性(P<0.05)。脂肪酸摄取抑制剂SSO可有效逆转CAOV3上清液诱导的CD4^(+)Treg脂质积累及PD-1、CTLA-4的高表达(P<0.05);而脂肪酸氧化抑制剂Etomoxir与合成抑制剂C75则无显著影响。结论:OV微环境通过促进CD4^(+)Treg的脂质摄取,提高细胞内脂质含量,促进其免疫抑制分子PD-1和CTLA-4表达。靶向脂肪酸摄取途径可能是逆转OV中Treg介导的免疫抑制的潜在策略。展开更多
Multiple sclerosis is a severe autoimmune disorder that is mainly mediated by pathogenic cluster of CD4^(+)T cell subsets.Despite advancements in the management of multiple sclerosis,there is a critical need for more ...Multiple sclerosis is a severe autoimmune disorder that is mainly mediated by pathogenic cluster of CD4^(+)T cell subsets.Despite advancements in the management of multiple sclerosis,there is a critical need for more effective and safer treatments.In the present study,we administered Lycium barbarum glycopeptide to a mouse model of experimental autoimmune encephalomyelitis-an animal model of multiple sclerosis-and evaluated its effects on pathogenic CD4^(+)T cell activation both in vivo and in vitro.Lycium barbarum glycopeptide significantly mitigated the clinical severity of experimental autoimmune encephalomyelitis,as demonstrated by reduced demyelination and neuroinflammation.Moreover,Lycium barbarum glycopeptide treatment decreased the infiltration of peripheral leukocytes into the central nervous system and suppressed pro-inflammatory cytokine expression.Lycium barbarum glycopeptide also modulated pathogenic CD4^(+)T cell activation by inhibiting T helper 1/T helper 17 cell differentiation while promoting regulatory T cell expansion.Notably,no side effects were observed,suggesting the long-term safety and tolerability of Lycium barbarum glycopeptide.Furthermore,RNA sequencing data indicated that Lycium barbarum glycopeptide inhibits activator protein-1,an essential regulator of T cell activation and differentiation.This finding was supported by the reversal of T helper/T helper 17 cell response suppression upon AP-1 blockade.Collectively,these results highlight the potential of Lycium barbarum glycopeptide as an innovative therapeutic agent for CD4^(+)T cell-associated autoimmune or inflammatory diseases,such as multiple sclerosis.展开更多
文摘目的:探究卵巢癌(ovarian cancer,OV)浸润性CD4^(+)调节性T细胞(regulatory T cell,Treg)的脂质摄取与积累情况,及其与CD4^(+)Treg中程序性细胞死亡蛋白1(programmed cell death protein 1,PD-1)和细胞毒性T淋巴细胞相关蛋白-4(cytotoxic Tlymphocyte associated protein 4,CTLA-4)表达的相关性。方法:采用亲脂性荧光染料BODIPY^(TM)493/503和荧光脂肪酸探针BODIPY^(TM)500/510 C1 C12分别检测OV组织中的或与不同OV细胞系(ES-2、SKOV3、CAOV3)上清液共培养的人源CD4^(+)Treg的细胞内脂质含量和脂质摄取能力;使用脂肪酸氧化抑制剂(Etomoxir)、脂肪酸合成抑制剂(C75)和脂肪酸摄取抑制剂磺基-N-琥珀酰亚胺油酸酯(sulfo-N-succinimidyl oleate,SSO)干预脂质代谢;通过流式细胞术分析CD4^(+)Treg上免疫抑制分子PD-1和CTLA-4的表达。结果:OV组织CD4^(+)Treg相比传统CD4^(+)T细胞表现出更高的脂质含量和脂质摄取能力(P均<0.01)。在体外实验中,与基础培养基相比,OV细胞培养上清可显著提升CD4^(+)Treg的胞内脂质含量与脂质摄取能力(P均<0.05),其中CAOV3来源的上清作用最为显著。此外,CAOV3上清液还能提升CD4^(+)Treg中PD-1与CTLA-4的表达(P<0.05)。CD4^(+)Treg的脂质积累随CAOV3上清浓度增加呈剂量依赖性上升(P<0.05),且其对胞外荧光脂肪酸类似物的摄取能力具有浓度依赖性(P<0.05)。脂肪酸摄取抑制剂SSO可有效逆转CAOV3上清液诱导的CD4^(+)Treg脂质积累及PD-1、CTLA-4的高表达(P<0.05);而脂肪酸氧化抑制剂Etomoxir与合成抑制剂C75则无显著影响。结论:OV微环境通过促进CD4^(+)Treg的脂质摄取,提高细胞内脂质含量,促进其免疫抑制分子PD-1和CTLA-4表达。靶向脂肪酸摄取途径可能是逆转OV中Treg介导的免疫抑制的潜在策略。
基金supported by the National Natural Science Foundational of China,Nos.U24A20692(to CJZ),82371355(to CJZ),and 82101414(to MH)National NaturalScience Foundational of China for Excellent Young Scholars,No.82022019(to CJZ)+5 种基金Sichuan Special Fund for Distinguished Young Scholars,No.24NSFJQ0052(to CJZ)The Innovationand Entrepreneurial Team of Sichuan Tianfu Emei Program,No.CZ2024018(to CJZ)Funding for Distinguished Young Scholars of Sichuan Provincial People’sHospital,No.30420230005Funding for Distinguished Young Scholars of University of Electronic Science and Technology of China,No.A1098531023601381(toCJZ)Sichuan Science and Technology Support Project,No.2023YFS0212(to BH)Project of Sichuan Provincial Health Commission,No.19PJ265(to LD).
文摘Multiple sclerosis is a severe autoimmune disorder that is mainly mediated by pathogenic cluster of CD4^(+)T cell subsets.Despite advancements in the management of multiple sclerosis,there is a critical need for more effective and safer treatments.In the present study,we administered Lycium barbarum glycopeptide to a mouse model of experimental autoimmune encephalomyelitis-an animal model of multiple sclerosis-and evaluated its effects on pathogenic CD4^(+)T cell activation both in vivo and in vitro.Lycium barbarum glycopeptide significantly mitigated the clinical severity of experimental autoimmune encephalomyelitis,as demonstrated by reduced demyelination and neuroinflammation.Moreover,Lycium barbarum glycopeptide treatment decreased the infiltration of peripheral leukocytes into the central nervous system and suppressed pro-inflammatory cytokine expression.Lycium barbarum glycopeptide also modulated pathogenic CD4^(+)T cell activation by inhibiting T helper 1/T helper 17 cell differentiation while promoting regulatory T cell expansion.Notably,no side effects were observed,suggesting the long-term safety and tolerability of Lycium barbarum glycopeptide.Furthermore,RNA sequencing data indicated that Lycium barbarum glycopeptide inhibits activator protein-1,an essential regulator of T cell activation and differentiation.This finding was supported by the reversal of T helper/T helper 17 cell response suppression upon AP-1 blockade.Collectively,these results highlight the potential of Lycium barbarum glycopeptide as an innovative therapeutic agent for CD4^(+)T cell-associated autoimmune or inflammatory diseases,such as multiple sclerosis.
